Discovery and Optimization of a Novel Series of Dyrk1B Kinase Inhibitors to Explore a Mek Resistance Hypothesis.
Kettle, J.G., Ballard, P., Bardelle, C., Cockerill, M., Colclough, N., Critchlow, S.E., Debreczeni, J.E., Fairley, G., Fillery, S., Graham, M.A., Goodwin, L., Guichard, S., Hudson, K., Ward, R.A., Whittaker, D.(2015) J Med Chem 58: 2834
- PubMed: 25738750 
- DOI: https://doi.org/10.1021/acs.jmedchem.5b00098
- Primary Citation of Related Structures:  
4D2R, 4D2S - PubMed Abstract: 
Potent and selective inhibitors of Dyrk1B kinase were developed to explore the hypothesis, based on siRNA studies, that Dyrk1B may be a resistance mechanism in cells undergoing a stress response.
Organizational Affiliation: 
Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.